How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
- PMID: 30244850
- DOI: 10.1016/j.jtho.2018.07.009
How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
Comment on
-
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.J Thorac Oncol. 2018 Oct;13(10):1530-1538. doi: 10.1016/j.jtho.2018.06.005. Epub 2018 Jun 20. J Thorac Oncol. 2018. PMID: 29935304 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical